Patents Assigned to Tri-lnstitutional Therapeutics Discovery Institute, Inc.
  • Publication number: 20210353607
    Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 18, 2021
    Applicants: Sloan-Kettering Institute for Cancer Research, Tri-lnstitutional Therapeutics Discovery Institute, Inc.
    Inventors: Makoto Fushimi, Maurizio Scaltriti, Daniel Alan Heller, Carles Monterrubio Martinez, Amaia Arruabarrena Aristorena, Peter T. Meinke, Michael Andrew Foley, Yasutomi Asano, Kazuyoshi Aso, Hiroki Takahagi, Yosef Shamay, Jose Manuel Baselga Torres, Yusuke Sasaki, Mayako Michino
  • Publication number: 20200062776
    Abstract: Hedgehog acyltransferase (Hhat), a membrane-bound O-acyl transferase (MBOAT) protein, is responsible for the palmitoylation of Shh and is crucial to proper Shh signaling. Hhat inhibitors that are capable of preventing Shh palmitoylation and mitigating Shh signaling, and therefore can be used in the treatment and/or prevention of diseases (e.g., proliferative diseases, such as cancer). Provided herein are Hhat inhibitors, such as compounds of Formula (I), (II), and (III), which are useful for the treatment and/or prevention of disease.
    Type: Application
    Filed: June 16, 2017
    Publication date: February 27, 2020
    Applicants: Memorial Sloan-Kettering Cancer Center, Tri-lnstitutional Therapeutics Discovery Institute, Inc.
    Inventors: Marilyn D. Resh, James John Asciolla, Brittany Haugen, Masanori Kawasaki, Tomoya Yukawa, Kazuyoshi Aso, Michael Andrew